Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 3/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 8/20 | 0.49 |
| ▸ | CACNA1I | Q9P0X4 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485782 | 0.92 | ELOVL1 (0.64) | ELOVL1CACNA1HCACNA1GCACNA1IKMT2A | |
| SCHEMBL20485329 | 0.85 | ELOVL1 (0.71) | ELOVL1CACNA1HCACNA1GCACNA1IKMT2A | |
| SCHEMBL20485270 | 0.80 | ELOVL1 (0.82) | ELOVL1CACNA1HCACNA1GCACNA1I | |
| SCHEMBL20250625 | 0.79 | ELOVL1 (0.64) | ELOVL1CACNA1HCACNA1GCACNA1IGAA | |
| SCHEMBL20242035 | 0.77 | ELOVL1 (0.50) | ELOVL1CACNA1HCACNA1GCACNA1IGAA | |
| SCHEMBL20250000 | 0.77 | ELOVL1 (0.82) | ELOVL1CACNA1HCACNA1GCACNA1ICACNA1C | |
| SCHEMBL20249818 | 0.76 | ELOVL1 (0.55) | ELOVL1 | |
| SCHEMBL20249957 | 0.76 | ELOVL1 (0.59) | ELOVL1CACNA1HCACNA1GCACNA1IWNT3A | |
| SCHEMBL20485468 | 0.76 | ELOVL1 (0.72) | ELOVL1 | |
| SCHEMBL20485322 | 0.76 | ELOVL1 (0.67) | ELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | claimed |
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | ELOVL1 39/4885CACNA1H 2998/4885CACNA1G 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.